Invigorate 发表于 2025-3-25 04:28:37

http://reply.papertrans.cn/3/237/23697/23697-21.png

迅速成长 发表于 2025-3-25 09:24:21

Submitted on: 13 October 2018.
Revised on: 21 October 2018.
Accepted on: 05 November 2018.
Ophthalmology and Therapy---SPRINGER INT PUBL AG

Common-Migraine 发表于 2025-3-25 12:37:53

Submitted on: 18 July 2022.
Revised on: 27 August 2022.
Accepted on: 03 September 2022.
Ophthalmology and Therapy

陈腐思想 发表于 2025-3-25 16:30:32

Submitted on: 03 August 2006.
Revised on: 11 September 2006.
Accepted on: 08 October 2006.
Ophthalmology and Therapy---SPRINGER INT PUBL AG

烧烤 发表于 2025-3-25 22:36:47

Submitted on: 15 February 2009.
Revised on: 25 March 2009.
Accepted on: 20 April 2009.
Ophthalmology and Therapy

forthy 发表于 2025-3-26 00:26:28

Submitted on: 21 November 2006.
Revised on: 05 December 2006.
Accepted on: 29 December 2006.
Ophthalmology and Therapy

吼叫 发表于 2025-3-26 04:45:13

http://reply.papertrans.cn/3/237/23697/23697-27.png

欢呼 发表于 2025-3-26 10:30:42

Submitted on: 01 July 2001.
Revised on: 11 July 2001.
Accepted on: 19 July 2001.
Ophthalmology and Therapy

BUDGE 发表于 2025-3-26 14:18:06

Submitted on: 02 May 2003.
Revised on: 30 May 2003.
Accepted on: 26 June 2003.
Ophthalmology and Therapy---SPRINGER INT PUBL AG

受人支配 发表于 2025-3-26 19:48:28

Submitted on: 01 August 2004.
Revised on: 04 September 2004.
Accepted on: 10 September 2004.
Ophthalmology and Therapy---SPRINGER INT PUBL AG
页: 1 2 [3] 4
查看完整版本: SCIE期刊Ophthalmology and Therapy 2024/2025影响因子:2.666 (OPHTHALMOL THER) (2193-8245). (OPHTHALMOLOGY)(眼科学)Science Citation